Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 43 Published: October 31, 2021 Report Code: GMDGDHC2983TDB

The metabotropic glutamate receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline market research report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key MoA in the metabotropic glutamate receptor 3 pipeline market?

The key MoA in the metabotropic glutamate receptor 3 pipeline market are Metabotropic Glutamate Receptor 3 Antagonist, and Metabotropic Glutamate Receptor 3 Agonist. Metabotropic Glutamate Receptor 3 Antagonist has the highest number of products in the metabotropic glutamate receptor 3 pipeline market.

Metabotropic glutamate receptor 3 pipeline market, by MoA

Metabotropic glutamate receptor 3 pipeline market, by MoA

For more MoA insights, download a free sample

What are the key RoA in the metabotropic glutamate receptor 3 pipeline market?

The key RoA in the metabotropic glutamate receptor 3 pipeline market are Oral and Intravenous. Oral has the highest number of pipeline products.

metabotropic glutamate receptor 3 pipeline market, by RoA

metabotropic glutamate receptor 3 pipeline market, by RoA

For more RoA insights, download a free sample

What are the key molecule types in the metabotropic glutamate receptor 3 pipeline market?

The key molecule type in the metabotropic glutamate receptor 3 pipeline market is small molecule.

What are the key companies in the metabotropic glutamate receptor 3 pipeline market?

The key companies in the metabotropic glutamate receptor 3 pipeline market are Addex Therapeutics Ltd, Camino Pharma LLC, Denovo Biopharma LLC, Eli Lilly and Co, Gate Neurosciences Inc, Mavalon Therapeutics Ltd (Inactive), Noema Pharma AG, and Taisho Pharmaceutical Holdings Co Ltd. Denovo Biopharma LLC has the highest number of pipeline products in the metabotropic glutamate receptor 3 pipeline market.

Metabotropic glutamate receptor 3 pipeline market by companies

Metabotropic glutamate receptor 3 pipeline market by companies

To know more about key companies, download a free sample

Market report overview

Key MoA Metabotropic Glutamate Receptor 3 Antagonist, and Metabotropic Glutamate Receptor 3 Agonist
Key RoA Oral and Intravenous
Key molecule type Small Molecule
Key companies Addex Therapeutics Ltd, Camino Pharma LLC, Denovo Biopharma LLC, Eli Lilly and Co, Gate Neurosciences Inc, Mavalon Therapeutics Ltd (Inactive), Noema Pharma AG, and Taisho Pharmaceutical Holdings Co Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
  • The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

  • Addex Therapeutics Ltd

    Camino Pharma LLC

    Denovo Biopharma LLC

    Eli Lilly and Co

    Gate Neurosciences Inc

    Mavalon Therapeutics Ltd (Inactive)

    Noema Pharma AG

    Taisho Pharmaceutical Holdings Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Overview

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Camino Pharma LLC

Denovo Biopharma LLC

Eli Lilly and Co

Gate Neurosciences Inc

Mavalon Therapeutics Ltd (Inactive)

Noema Pharma AG

Taisho Pharmaceutical Holdings Co Ltd

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Drug Profiles

DT-011088 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GATE-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3020371 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOE-109 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomaglumetad methionil – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-9881 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-134 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-161 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0650786 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Dormant Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Discontinued Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Product Development Milestones

Featured News & Press Releases

Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study

Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research

Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Addex Therapeutics Ltd, 2021

Pipeline by Camino Pharma LLC, 2021

Pipeline by Denovo Biopharma LLC, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by Gate Neurosciences Inc, 2021

Pipeline by Mavalon Therapeutics Ltd (Inactive), 2021

Pipeline by Noema Pharma AG, 2021

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.